Recent Updates
Recently added Catalysts

Humalog Mix 50

Phase 3

Diabetes Mellitus, Type 1 | Small molecule | Metabolic |Eli Lilly and Company|Last Updated: Jul 31, 2006

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment120

FDA Designations

No designations recorded

Clinical trial landscape

Humalog Mix 50 · 1 trial · 2 indications

Phase 3 1
NCT00191581Local Registration Trial in China Humalog Mix 50Diabetes Mellitus, Type 1
COMPLETED120 Analytics
PHASE3COMPLETED
Local Registration Trial in China Humalog Mix 50
Diabetes Mellitus, Type 1
NCT00191581120
Unlock trial analytics

Study Endpoints

Primary Endpoints

The primary objective of this study is to compare the 2-hour PPBG excursion following a standard test meal in IDDM patients treated BID with human insulin mix 50/50, vs the 2-hour PPBG excursion in patients treated BID with insulin lispro mix 50/50

Secondary Endpoints

The secondary objectives of the study are:
Assess hemoglobin A1c (HbA1c) values at baseline and after treatment with insulin lispro mix 50/50.
Assess HbA1c values at baseline and after treatment with human insulin mix 50/50.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Interventions

NameTypeDescription
Humalog Mix 50DRUG -
Human Insulin Mix 50:50DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: 1. Men and women who have had either type 1 or type 2 diabetes (World Health Organization\[WHO\]classification)for at least 2 months and are between the ages of 18 and 70 (inclusive) at the signing of the informed consent. 2. Have been treated with commercially available human i...

Countries:China
Unlock Eligibility Criteria

Frequently asked questions about Humalog Mix 50

What is Humalog Mix 50 used for?

Humalog Mix 50 is used for the treatment of Diabetes Mellitus, Type 1. It is a small molecule developed by Eli Lilly and Company for the metabolic therapeutic area. The drug is currently in Phase 3 clinical development.

Who makes Humalog Mix 50?

Humalog Mix 50 is developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker LLY. The drug is being studied for the treatment of Type 1 Diabetes Mellitus.

What phase is Humalog Mix 50 in?

Humalog Mix 50 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed for this asset.

What clinical trials is Humalog Mix 50 in?

Humalog Mix 50 has one completed Phase 3 clinical trial with the identifier NCT00191581, titled 'Local Registration Trial in China Humalog Mix 50'. This trial enrolled 120 participants and was conducted in China.

Is Humalog Mix 50 the same as other insulin products?

Humalog Mix 50 is a specific premixed insulin formulation. It is developed by Eli Lilly and Company and is being studied for Type 1 Diabetes Mellitus. The drug is currently in Phase 3 clinical trials.